Intrinsic value of Sarepta Therapeutics, Inc. - SRPT

Previous Close

$129.88

  Intrinsic Value

$3.58

stock screener

  Rating & Target

str. sell

-97%

Previous close

$129.88

 
Intrinsic value

$3.58

 
Up/down potential

-97%

 
Rating

str. sell

We calculate the intrinsic value of SRPT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 9.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  47.40
  43.16
  39.34
  35.91
  32.82
  30.04
  27.53
  25.28
  23.25
  21.43
  19.78
  18.31
  16.98
  15.78
  14.70
  13.73
  12.86
  12.07
  11.36
  10.73
  10.15
  9.64
  9.18
  8.76
  8.38
  8.04
  7.74
  7.47
  7.22
  7.00
Revenue, $m
  444
  635
  885
  1,203
  1,598
  2,078
  2,650
  3,319
  4,091
  4,968
  5,951
  7,040
  8,235
  9,534
  10,936
  12,437
  14,036
  15,730
  17,518
  19,397
  21,367
  23,427
  25,576
  27,816
  30,148
  32,573
  35,094
  37,714
  40,436
  43,266
Variable operating expenses, $m
  936
  1,339
  1,865
  2,534
  3,366
  4,377
  5,581
  6,992
  8,617
  10,463
  12,532
  14,826
  17,343
  20,079
  23,031
  26,193
  29,560
  33,128
  36,893
  40,851
  44,999
  49,337
  53,864
  58,581
  63,491
  68,599
  73,908
  79,425
  85,159
  91,118
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  936
  1,339
  1,865
  2,534
  3,366
  4,377
  5,581
  6,992
  8,617
  10,463
  12,532
  14,826
  17,343
  20,079
  23,031
  26,193
  29,560
  33,128
  36,893
  40,851
  44,999
  49,337
  53,864
  58,581
  63,491
  68,599
  73,908
  79,425
  85,159
  91,118
Operating income, $m
  -492
  -704
  -980
  -1,332
  -1,768
  -2,299
  -2,932
  -3,672
  -4,526
  -5,496
  -6,581
  -7,786
  -9,108
  -10,545
  -12,095
  -13,756
  -15,524
  -17,398
  -19,375
  -21,454
  -23,632
  -25,910
  -28,288
  -30,765
  -33,344
  -36,026
  -38,814
  -41,712
  -44,723
  -47,852
EBITDA, $m
  -474
  -679
  -946
  -1,285
  -1,707
  -2,220
  -2,831
  -3,547
  -4,372
  -5,309
  -6,359
  -7,523
  -8,800
  -10,189
  -11,686
  -13,291
  -15,000
  -16,810
  -18,721
  -20,729
  -22,834
  -25,035
  -27,332
  -29,726
  -32,218
  -34,809
  -37,503
  -40,303
  -43,213
  -46,236
Interest expense (income), $m
  2
  23
  36
  56
  81
  114
  155
  205
  264
  334
  414
  505
  606
  719
  843
  978
  1,123
  1,279
  1,444
  1,620
  1,805
  2,000
  2,204
  2,417
  2,640
  2,872
  3,114
  3,365
  3,626
  3,898
  4,180
Earnings before tax, $m
  -515
  -739
  -1,036
  -1,413
  -1,883
  -2,454
  -3,137
  -3,937
  -4,860
  -5,909
  -7,086
  -8,393
  -9,827
  -11,388
  -13,073
  -14,879
  -16,803
  -18,842
  -20,995
  -23,259
  -25,632
  -28,114
  -30,705
  -33,405
  -36,216
  -39,140
  -42,179
  -45,338
  -48,621
  -52,032
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -515
  -739
  -1,036
  -1,413
  -1,883
  -2,454
  -3,137
  -3,937
  -4,860
  -5,909
  -7,086
  -8,393
  -9,827
  -11,388
  -13,073
  -14,879
  -16,803
  -18,842
  -20,995
  -23,259
  -25,632
  -28,114
  -30,705
  -33,405
  -36,216
  -39,140
  -42,179
  -45,338
  -48,621
  -52,032

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  946
  1,354
  1,887
  2,565
  3,407
  4,430
  5,649
  7,078
  8,723
  10,592
  12,688
  15,010
  17,558
  20,329
  23,317
  26,518
  29,928
  33,540
  37,352
  41,359
  45,559
  49,950
  54,533
  59,309
  64,281
  69,451
  74,827
  80,413
  86,218
  92,251
Adjusted assets (=assets-cash), $m
  946
  1,354
  1,887
  2,565
  3,407
  4,430
  5,649
  7,078
  8,723
  10,592
  12,688
  15,010
  17,558
  20,329
  23,317
  26,518
  29,928
  33,540
  37,352
  41,359
  45,559
  49,950
  54,533
  59,309
  64,281
  69,451
  74,827
  80,413
  86,218
  92,251
Revenue / Adjusted assets
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
  0.469
Average production assets, $m
  113
  161
  225
  306
  406
  528
  673
  843
  1,039
  1,262
  1,511
  1,788
  2,092
  2,422
  2,778
  3,159
  3,565
  3,996
  4,450
  4,927
  5,427
  5,950
  6,496
  7,065
  7,658
  8,273
  8,914
  9,579
  10,271
  10,989
Working capital, $m
  116
  166
  231
  314
  417
  542
  692
  866
  1,068
  1,297
  1,553
  1,837
  2,149
  2,488
  2,854
  3,246
  3,663
  4,106
  4,572
  5,063
  5,577
  6,114
  6,675
  7,260
  7,869
  8,501
  9,159
  9,843
  10,554
  11,292
Total debt, $m
  662
  1,030
  1,509
  2,119
  2,877
  3,798
  4,895
  6,181
  7,662
  9,344
  11,230
  13,320
  15,613
  18,107
  20,796
  23,677
  26,746
  29,997
  33,427
  37,034
  40,814
  44,766
  48,891
  53,189
  57,663
  62,317
  67,155
  72,182
  77,407
  82,836
Total liabilities, $m
  851
  1,219
  1,698
  2,308
  3,066
  3,987
  5,084
  6,370
  7,851
  9,533
  11,419
  13,509
  15,803
  18,296
  20,985
  23,866
  26,935
  30,186
  33,617
  37,223
  41,003
  44,955
  49,080
  53,378
  57,853
  62,506
  67,344
  72,372
  77,596
  83,026
Total equity, $m
  95
  135
  189
  256
  341
  443
  565
  708
  872
  1,059
  1,269
  1,501
  1,756
  2,033
  2,332
  2,652
  2,993
  3,354
  3,735
  4,136
  4,556
  4,995
  5,453
  5,931
  6,428
  6,945
  7,483
  8,041
  8,622
  9,225
Total liabilities and equity, $m
  946
  1,354
  1,887
  2,564
  3,407
  4,430
  5,649
  7,078
  8,723
  10,592
  12,688
  15,010
  17,559
  20,329
  23,317
  26,518
  29,928
  33,540
  37,352
  41,359
  45,559
  49,950
  54,533
  59,309
  64,281
  69,451
  74,827
  80,413
  86,218
  92,251
Debt-to-equity ratio
  7.000
  7.600
  8.000
  8.260
  8.440
  8.570
  8.670
  8.730
  8.780
  8.820
  8.850
  8.870
  8.890
  8.910
  8.920
  8.930
  8.940
  8.940
  8.950
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -515
  -739
  -1,036
  -1,413
  -1,883
  -2,454
  -3,137
  -3,937
  -4,860
  -5,909
  -7,086
  -8,393
  -9,827
  -11,388
  -13,073
  -14,879
  -16,803
  -18,842
  -20,995
  -23,259
  -25,632
  -28,114
  -30,705
  -33,405
  -36,216
  -39,140
  -42,179
  -45,338
  -48,621
  -52,032
Depreciation, amort., depletion, $m
  18
  25
  34
  46
  61
  79
  100
  125
  154
  187
  222
  263
  308
  356
  408
  465
  524
  588
  654
  725
  798
  875
  955
  1,039
  1,126
  1,217
  1,311
  1,409
  1,510
  1,616
Funds from operations, $m
  -497
  -715
  -1,001
  -1,367
  -1,822
  -2,376
  -3,037
  -3,812
  -4,706
  -5,723
  -6,864
  -8,130
  -9,520
  -11,032
  -12,664
  -14,414
  -16,278
  -18,255
  -20,341
  -22,534
  -24,834
  -27,239
  -29,750
  -32,366
  -35,090
  -37,923
  -40,868
  -43,929
  -47,110
  -50,416
Change in working capital, $m
  37
  50
  65
  83
  103
  125
  149
  175
  201
  229
  257
  284
  312
  339
  366
  392
  417
  442
  467
  490
  514
  538
  561
  585
  609
  633
  658
  684
  711
  738
Cash from operations, $m
  -534
  -765
  -1,067
  -1,450
  -1,925
  -2,501
  -3,186
  -3,986
  -4,907
  -5,951
  -7,120
  -8,414
  -9,831
  -11,371
  -13,030
  -14,806
  -16,696
  -18,697
  -20,807
  -23,025
  -25,348
  -27,777
  -30,311
  -32,951
  -35,698
  -38,556
  -41,526
  -44,613
  -47,821
  -51,155
Maintenance CAPEX, $m
  -11
  -17
  -24
  -33
  -45
  -60
  -78
  -99
  -124
  -153
  -186
  -222
  -263
  -308
  -356
  -408
  -465
  -524
  -588
  -654
  -725
  -798
  -875
  -955
  -1,039
  -1,126
  -1,217
  -1,311
  -1,409
  -1,510
New CAPEX, $m
  -36
  -49
  -63
  -81
  -100
  -122
  -145
  -170
  -196
  -223
  -250
  -277
  -304
  -330
  -356
  -381
  -406
  -430
  -454
  -477
  -500
  -523
  -546
  -569
  -592
  -616
  -640
  -665
  -692
  -719
Cash from investing activities, $m
  -47
  -66
  -87
  -114
  -145
  -182
  -223
  -269
  -320
  -376
  -436
  -499
  -567
  -638
  -712
  -789
  -871
  -954
  -1,042
  -1,131
  -1,225
  -1,321
  -1,421
  -1,524
  -1,631
  -1,742
  -1,857
  -1,976
  -2,101
  -2,229
Free cash flow, $m
  -581
  -830
  -1,154
  -1,564
  -2,070
  -2,682
  -3,409
  -4,256
  -5,227
  -6,327
  -7,555
  -8,913
  -10,398
  -12,009
  -13,742
  -15,596
  -17,566
  -19,652
  -21,849
  -24,156
  -26,573
  -29,098
  -31,732
  -34,475
  -37,330
  -40,298
  -43,383
  -46,590
  -49,921
  -53,384
Issuance/(repayment) of debt, $m
  242
  367
  480
  610
  758
  921
  1,098
  1,285
  1,481
  1,682
  1,886
  2,090
  2,293
  2,493
  2,689
  2,881
  3,068
  3,251
  3,430
  3,606
  3,780
  3,952
  4,125
  4,298
  4,474
  4,654
  4,838
  5,028
  5,225
  5,429
Issuance/(repurchase) of shares, $m
  577
  780
  1,089
  1,481
  1,967
  2,557
  3,259
  4,080
  5,024
  6,096
  7,296
  8,625
  10,082
  11,665
  13,372
  15,199
  17,144
  19,204
  21,376
  23,659
  26,052
  28,553
  31,163
  33,883
  36,713
  39,657
  42,717
  45,897
  49,201
  52,636
Cash from financing (excl. dividends), $m  
  819
  1,147
  1,569
  2,091
  2,725
  3,478
  4,357
  5,365
  6,505
  7,778
  9,182
  10,715
  12,375
  14,158
  16,061
  18,080
  20,212
  22,455
  24,806
  27,265
  29,832
  32,505
  35,288
  38,181
  41,187
  44,311
  47,555
  50,925
  54,426
  58,065
Total cash flow (excl. dividends), $m
  238
  318
  415
  527
  654
  795
  948
  1,109
  1,278
  1,452
  1,626
  1,802
  1,977
  2,150
  2,319
  2,484
  2,646
  2,803
  2,958
  3,109
  3,259
  3,408
  3,556
  3,706
  3,858
  4,012
  4,171
  4,335
  4,505
  4,681
Retained Cash Flow (-), $m
  -577
  -780
  -1,089
  -1,481
  -1,967
  -2,557
  -3,259
  -4,080
  -5,024
  -6,096
  -7,296
  -8,625
  -10,082
  -11,665
  -13,372
  -15,199
  -17,144
  -19,204
  -21,376
  -23,659
  -26,052
  -28,553
  -31,163
  -33,883
  -36,713
  -39,657
  -42,717
  -45,897
  -49,201
  -52,636
Prev. year cash balance distribution, $m
  1,000
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  660
  -462
  -674
  -954
  -1,312
  -1,761
  -2,311
  -2,970
  -3,746
  -4,645
  -5,669
  -6,823
  -8,105
  -9,515
  -11,053
  -12,714
  -14,498
  -16,400
  -18,418
  -20,550
  -22,793
  -25,146
  -27,607
  -30,177
  -32,855
  -35,644
  -38,546
  -41,562
  -44,697
  -47,954
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  633
  -423
  -587
  -785
  -1,017
  -1,278
  -1,561
  -1,856
  -2,152
  -2,435
  -2,692
  -2,911
  -3,082
  -3,194
  -3,245
  -3,231
  -3,155
  -3,020
  -2,836
  -2,611
  -2,358
  -2,086
  -1,809
  -1,537
  -1,278
  -1,040
  -827
  -643
  -488
  -361
Current shareholders' claim on cash, %
  33.2
  17.3
  9.1
  4.9
  2.6
  1.4
  0.8
  0.4
  0.2
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

FINANCIAL RATIOS  of  Sarepta Therapeutics, Inc. (SRPT)

Valuation Ratios
P/E Ratio -26.6
Price to Sales 1422.4
Price to Book 21.1
Price to Tangible Book
Price to Cash Flow -28.9
Price to Free Cash Flow -28.1
Growth Rates
Sales Growth Rate 400%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 40%
Cap. Spend. - 3 Yr. Gr. Rate 11.8%
Financial Strength
Quick Ratio 32
Current Ratio 0.5
LT Debt to Equity 1.8%
Total Debt to Equity 4.7%
Interest Coverage -133
Management Effectiveness
Return On Assets -75.9%
Ret/ On Assets - 3 Yr. Avg. -66.4%
Return On Total Capital -94.3%
Ret/ On T. Cap. - 3 Yr. Avg. -81.1%
Return On Equity -101.3%
Return On Equity - 3 Yr. Avg. -85.6%
Asset Turnover 0
Profitability Ratios
Gross Margin 100%
Gross Margin - 3 Yr. Avg. 33.3%
EBITDA Margin -5180%
EBITDA Margin - 3 Yr. Avg. -9300%
Operating Margin -5340%
Oper. Margin - 3 Yr. Avg. -9560%
Pre-Tax Margin -5340%
Pre-Tax Margin - 3 Yr. Avg. -9566.7%
Net Profit Margin -5340%
Net Profit Margin - 3 Yr. Avg. -9566.7%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

SRPT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the SRPT stock intrinsic value calculation we used $301 million for the last fiscal year's total revenue generated by Sarepta Therapeutics, Inc.. The default revenue input number comes from 0001 income statement of Sarepta Therapeutics, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our SRPT stock valuation model: a) initial revenue growth rate of 47.4% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for SRPT is calculated based on our internal credit rating of Sarepta Therapeutics, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Sarepta Therapeutics, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of SRPT stock the variable cost ratio is equal to 211%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for SRPT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Sarepta Therapeutics, Inc..

Corporate tax rate of 27% is the nominal tax rate for Sarepta Therapeutics, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the SRPT stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for SRPT are equal to 25.4%.

Life of production assets of 6.8 years is the average useful life of capital assets used in Sarepta Therapeutics, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for SRPT is equal to 26.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1032.276 million for Sarepta Therapeutics, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 71.284 million for Sarepta Therapeutics, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Sarepta Therapeutics, Inc. at the current share price and the inputted number of shares is $9.3 billion.

RELATED COMPANIES Price Int.Val. Rating
BCRX BioCryst Pharm 3.69 0.11  str.sell
GILD Gilead Science 69.38 134.02  str.buy
PTCT PTC Therapeuti 43.65 2.84  str.sell
VRTX Vertex Pharmac 183.97 476.14  str.buy
ALNY Alnylam Pharma 74.37 3.06  str.sell
BMRN BioMarin Pharm 87.91 4.60  str.sell
FGEN FibroGen, Inc 44.31 130.70  str.buy

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.